• Aurinia Pharmaceuticals highlighted 2026 total revenue guidance of USD 315 million to USD 325 million; net product sales guidance of USD 305 million to USD 315 million.
• For the three months ended March 31, 2026, total revenue rose to USD 77.7 million from USD 62.5 million; net income increased to USD 34.4 million.
• Operating cash flow for the quarter climbed to USD 32.6 million from USD 1.3 million, reflecting improved profitability and cash generation.
• LUPKYNIS posted a 40.8% complete renal response rate at week 52 in AURORA 1 versus 22.5% for placebo; week 24 was 32.4% versus 19.7%.
• New EULAR 2026 analysis cited a 53% lower risk of renal-related event or death for LUPKYNIS versus placebo, with hazard ratio 0.467.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.